The placenta synthesizes and secretes protein and peptide hormones that are active both in the fetalmaternal compartment and within the placenta. These hormones include human chorionic gonadotropin (hCG) , the dimeric glycoprotein hormone that regulates progesterone production from the corpus luteum and placenta. A placental gonadotropin releasing hormone (GnRH) has been postulated as a local modulator of hCG secretion and a role for placental Inhibin has also been postulated in the feedback control of hCG secretion.l-' The Inhibins are part of a complex interrelated group of gonadal proteins that modulate FSH secretion by the pituitary. They have a molecular mass of 32 kD and are composed of common 01 subunits with similar but distinguishable {j subunits.
In pregnancies affected by Trisomy 21 there is an increased output of hCG, such that measurement of maternal serum total hCG levels have been proposed as a second trimester screening test for pregnancies affected by Trisomy 21. 3 More recently, the measurement of the Free {j subunit of hCG has been shown to be a superior marker for this condition across both the first" and second trimester of pregnancy.S In gestational trophoblastic disease such as hydatidiform mole, serum inhibin immunoreactivity has been shown to be significantly elevated and levels fall to normal menstrual cycle levels after evacuation of the mole. Furthermore, serum inhibin immunoreactivity in such cases prior to evacuation are highly correlated with Total hCG concentrations," Kratzner et al. 6 showed that in cases of Trisomy 21 the hCG bioactivity was not
increased. Thus, increased levels of hCG in Trisomy 21 are possibly due to altered synthesis or feedback control, in which serum inhibin may playa part. In order to assess further the mechanisms involved in hCG regulation in cases of Trisomy 21 we have undertaken a study of maternal serum Inhibin immunoreactivity in a randomly selected group of Trisomy 21 cases.
Fifteen maternal serum samples from our frozen store of second trimester pregnancies affected by Down's syndrome were selected at random. For each case, five control unaffected samples matched for maternal age, gestational age and length of storage, were similarly identified. Maternal serum Inhibin immunoreactivity was measured using an ELISA assay (Medgenex, High Wycombe, UK) incorporating capture and detector antibodies raised to the N terminal amino acid sequence of the 01 subunit of human Inhibin. Free {j (hCG) levels were previously determined with an immunoradiometric assay (CIS, High Wycombe, UK). S Results for each set of matched controls were ranked in ascending order and the median value determined. The level in each Trisomy 21 case was then expressed as a multiple of the median (MoM) value as shown in Table 1 . The median MoM in affected cases was 3·65 for Inhibin imunoreactivity and 2' 70 for Free {j (hCG). The distribution of Free {j (hCG) in unaffected and affected cases is known to fit a loglo gaussian distribution.I-' In this study the mean log Free {j MoM was 0·43319 with a standard deviation of O'2536, whilst the distribution for Inhibin immunoreactivity had a mean log MoM of 0 .48291 with a standard deviation of 0'43229, i.e. a significantly wider distribution than that for Free {j (hCG). The correlation between Inhibin immunoreactivity and Free {j (hCG), was 0·735 (Log Free (j MoM = Log Inhibin MoM x i -254-0'060). 1·17  4·33  5·88  16 These data are consistent with the hypothesis that Inhibin release is stimulated by increased concentrations of hCG and hence in Down's syndrome the elevated levels of Inhibin could provide evidence that this part of the feedback control circuit is functional.
The broader spread of Inhibin immunoreactivity levels in Down's syndrome and the high positive correlation with Free fJ (hCG) are likely to argue against the use of Inhibin immunoreactivity as an additional biochemical marker in Down's syndrome screening programmes.
